DE2061698A1 - Ovulation inhibitors contg spironolactone - with reduced side effects - Google Patents
Ovulation inhibitors contg spironolactone - with reduced side effectsInfo
- Publication number
- DE2061698A1 DE2061698A1 DE19702061698 DE2061698A DE2061698A1 DE 2061698 A1 DE2061698 A1 DE 2061698A1 DE 19702061698 DE19702061698 DE 19702061698 DE 2061698 A DE2061698 A DE 2061698A DE 2061698 A1 DE2061698 A1 DE 2061698A1
- Authority
- DE
- Germany
- Prior art keywords
- spironolactone
- side effects
- ovulation
- contg
- ovulation inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003433 contraceptive agent Substances 0.000 title claims abstract description 14
- 229960002256 spironolactone Drugs 0.000 title claims abstract description 8
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 title claims abstract description 8
- 230000000694 effects Effects 0.000 title abstract description 7
- 230000002051 biphasic effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 abstract description 8
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 206010030113 Oedema Diseases 0.000 abstract description 3
- 239000000262 estrogen Substances 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 abstract description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- -1 ethynyl oestrenol Chemical compound 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Arzneimittel Die Erfindung betrifft ein Arzneimittel mit einem beliebigen Gehalt von monophasischen oder biphasischen Ovulationshemmern. Medicaments The invention relates to a medicament with any Content of monophasic or biphasic ovulation inhibitors.
Alle Ovulationshemmer, wie beispielsweise Mischungen aus Norgestrel und Äthinylöntradiol, aus Mestranol und Xthynodioldiacetat oder aus Äthinylöstrenol und Nestranol, enthalten ein Gestagen und ein Östrogen. Während bei den monophasischen Ovulationshemmern ein Gestagen und ein Östrogen in allen Tabletten enthalten ist, enthalten die biphasischen Ovulationshemmer das Gestagen nur während der zweiten Phase der Tabletteneinnahme. Gestagene haben eine unerwünschte Nebenwirkung, die darin liegt, daß sie genau wie Aldosteron die Natriumanreicherung im Körper und damit die Ödembildung und den Bluthochdruck fördern. Der Mechanismus der Natriumanreichung ist bei Gestagenen und Aldosteron identisch.All ovulation inhibitors, such as mixtures of norgestrel and ethynyl oestradiol, from mestranol and xthynodiol diacetate or from ethynyl oestrenol and Nestranol, contain a progestin and an estrogen. While with the monophasic Ovulation inhibitors contain a progestogen and an estrogen in all tablets, The biphasic ovulation inhibitors contain the progestin only during the second Tablet-taking phase. Progestins have an undesirable side effect, the lies in the fact that, like aldosterone, it increases the accumulation of sodium in the body and thus promote edema formation and high blood pressure. The mechanism of sodium enrichment is identical for progestins and aldosterone.
Bisher versuchte man, die Ödembildung und den Bluthochdruck durch Diuretika zu verhindern, die jedoch teilweise sehr unangenehme Nebenwirkungen haben, da sie keine spezifischen Aldosteronantagonisten darstellen, sondern über einen anderen Mechanismus wirken.So far, attempts have been made to prevent edema and high blood pressure To prevent diuretics, some of which have very unpleasant side effects, since they are not specific aldosterone antagonists, but via one act different mechanism.
Aufgabe der Erfindung ist eg einen Ovulationshemmer zu schaffen, bei dem die durch das Gastagen hervorgerufenen Nebenwirkungen weitgehend aufgehoben sind.The object of the invention is eg to create an ovulation inhibitor which largely eliminated the side effects caused by gas days are.
Erfindungsgemäß wird diese Aufgabe durch ein Arzneimittel gelöst, das aus einer Mischung eines beliebigen Ovulationshemmers mit Spironolactone besteht. Der Vorteil des Zusatzes von Spironolactone liegt darin, daß dieses ein spezifischer Antagonist der unerwünschten Aldosteron-artigen Nebenwirkungen der Gestagen ist und auch keine weiteren unerwünschten Nebenwirkungen hervorruft.According to the invention, this object is achieved by a medicament, which consists of a mixture of any ovulation inhibitor with spironolactone. The advantage of adding spironolactone is that it is a specific one Antagonist of the unwanted aldosterone-like side effects of progestin and also does not cause any other undesirable side effects.
Im Sinne des Erfindungsgedankens lassen sich monophasische und biphasische Ovulationshemmer mit Spironolactone mischen.In terms of the concept of the invention, monophasic and biphasic Mix ovulation inhibitor with spironolactone.
Bei biphasischen Ovulationshemmern ist die Kombination mit Spironolactone aber nicht so wesentlich, weil bei diesen dae Ges tagen nur während einer sehr viel kürzeren Zeitspanne eingenemmen wird.In the case of biphasic ovulation inhibitors, the combination with spironolactone but not so essential, because with these dae tales only during one very much shorter period of time.
Das erfindungsgemäße ArzneiMittel wird zweckmäßigerweise in Tablettenform hergestellt wie alfe bisher auf dea Markt befindlichen Ovulationshemmer. Jede Tablette enthält vorzugsweise etwa 10 - 15 mg Spironelactone.The medicament according to the invention is expediently in tablet form manufactured like all ovulation inhibitors currently on the market. Any tablet preferably contains about 10-15 mg of spironelactones.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702061698 DE2061698A1 (en) | 1970-12-15 | 1970-12-15 | Ovulation inhibitors contg spironolactone - with reduced side effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702061698 DE2061698A1 (en) | 1970-12-15 | 1970-12-15 | Ovulation inhibitors contg spironolactone - with reduced side effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2061698A1 true DE2061698A1 (en) | 1972-07-06 |
Family
ID=5791042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19702061698 Pending DE2061698A1 (en) | 1970-12-15 | 1970-12-15 | Ovulation inhibitors contg spironolactone - with reduced side effects |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2061698A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
-
1970
- 1970-12-15 DE DE19702061698 patent/DE2061698A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2711493C2 (en) | ||
| DE69118494T2 (en) | Contraception procedure and scheme | |
| DE69118493T2 (en) | Oral contraceptive with low estrogen content | |
| EP0310541B1 (en) | Antigestagenic and antioestrogenic compounds for the introduction of labour and interruption of pregnancy, as well as for the treatment of gynecologic disorders | |
| EP0628312B1 (en) | Anti-contraceptive composition | |
| DE69117902T2 (en) | Progestogen as the only contraceptive | |
| EP0868188B1 (en) | Kit for female mammals, comprising a combination of gestagen and oestrogen | |
| DE19737348C2 (en) | Pharmaceutical composition containing clindamycin and clotrimazole | |
| DE4313926A1 (en) | Multiphase pharmaceutical product for hormonal contraception | |
| DE1617686A1 (en) | Method for stimulating ovulation cycles and pharmaceutical packaging units | |
| DE2434849C2 (en) | Cardio-strengthening dosage unit with gelatin capsule | |
| DE2313635A1 (en) | ANTIDEPRESSANT | |
| DE2061698A1 (en) | Ovulation inhibitors contg spironolactone - with reduced side effects | |
| DE69827017T2 (en) | COMBINATIONS OF ENDOMETRICALLY PROTECTED AND ENDOMETRICALLY ATROPHOSED AGENTS WITH ESTROGENIC IN ORAL CONCENTRATION PREVENTION | |
| DE69430996T2 (en) | METHOD FOR DRY MIX COMPRESSION OF MEDICINAL PRODUCTS | |
| DE60035771T2 (en) | Use of a plasma homocysteine content reducing agent to reduce the risk of gestagen type hormone-induced thromboembolic side effects | |
| EP0296097B1 (en) | Medicine containing inhibitors of the progesterone synthesis of the trilostane or epostane type and antigestagens | |
| DE102006003509A1 (en) | contraceptive | |
| DE2008621A1 (en) | Contraceptives | |
| DE3744054A1 (en) | USE OF ANTIGESTAGES FOR THE PRODUCTION OF MEDICINAL PRODUCTS | |
| DE69931696T2 (en) | Medicines for reducing effects during or after menopause and methods of treating and using same | |
| DE2520338A1 (en) | PHARMACEUTICAL DOSING UNIT FOR STEROID | |
| DE1928518A1 (en) | Pharmaceutical mass | |
| DE2146239A1 (en) | New contraceptive means | |
| DE2401449A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE RELIEF OF SKIN PROLIFERATIONAL DISEASES |